Cargando…
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLBCL) have shown negative results, which may be due in part to onerous eligibility criteria limiting enrollment of poor-risk patients who require immediate treatment. We conducted a Delphi-method...
Autores principales: | Harkins, R. Andrew, Patel, Sharvil P., Lee, Michelle J., Switchenko, Jeffrey M., Ansell, Stephen M., Bartlett, Nancy L., Blum, Kristie A., Cashen, Amanda F., Casulo, Carla, Friedberg, Jonathan W., Johnston, Patrick B., Kahl, Brad S., Leonard, John P., Link, Brian K., Lossos, Izidore S., Martin, Peter, Maurer, Matt J., Mehta-Shah, Neha, Reagan, Patrick M., Westin, Jason R., Koff, Jean L., Flowers, Christopher R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092417/ https://www.ncbi.nlm.nih.gov/pubmed/35100356 http://dx.doi.org/10.1182/bloodadvances.2021006504 |
Ejemplares similares
-
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022) -
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
por: Russler-Germain, David A., et al.
Publicado: (2023) -
The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021) -
A germinal center–associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL
por: Miyawaki, Kohta, et al.
Publicado: (2022) -
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
por: Oien, Derek B., et al.
Publicado: (2023)